ProQR Reports Initial Safety Data for AX-0810, Updates 2026 Milestones
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
ProQR Therapeutics (PRQR) announced encouraging initial safety and PK data from the first cohort of healthy volunteers in its ongoing Phase 1 trial of AX-0810 and provided an update on broader pipeline progress and anticipated 2026 milestones. "The initial human data from AX-0810 mark an important early milestone for ProQR, providing safety and pharmacokinetic observations in healthy volunteers," said Cristina Lopez Lopez, MD, PhD, Chief Medical Officer of ProQR. "These data support continued dosing and position us well for the upcoming target engagement readout in the first half of 2026." Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohort. Development Candidates selected for pipeline programs AX-2402 for Rett syndrome and AX-2911 for MASH. Strategic collaboration with Eli Lilly (LLY) achieved $4.5 million in milestones in 2025, contributing to strong financial position with runway into mid-2027
Get Free Real-Time Notifications for Any Stock
Monitor tickers like LLY with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1023.800
Low
950.00
Averages
1192
High
1500
Current: 1023.800
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Announces Eli Lilly's Plan for Six Major U.S. Manufacturing Plants
- Manufacturing Expansion: Eli Lilly plans to build six major manufacturing plants in the U.S., demonstrating a strong commitment to the American market, which is expected to significantly enhance its production capacity and market share.
- Investment Commitment: The company pledged to invest over $50 billion in domestic medicine production last year, indicating its crucial role in the revival of U.S. manufacturing, potentially boosting local economic growth and job opportunities.
- Site Selection Strategy: Alabama, Virginia, and Texas have been identified as locations for three of the plants, further solidifying the company's presence in the southern market and enhancing supply chain flexibility.
- Industry Impact: Lilly's expansion plan is likely to not only bolster its competitiveness in the obesity drug sector but also prompt other pharmaceutical companies to increase their investments in the U.S., fostering a positive competitive environment within the industry.
Continue Reading
Trump to Announce Fed Chair Nominee Next Week
- Fed Chair Nomination: Trump announced during a Cabinet meeting that he will nominate a new Fed Chair next week, with candidates including NEC Director Kevin Hassett and Fed Governor Christopher Waller, which could influence market expectations regarding monetary policy.
- Drug Label Update: UK regulators are updating product labels for GLP-1 drugs to warn of severe acute pancreatitis risks, affecting Novo Nordisk's semaglutide and Eli Lilly's Zepbound, potentially impacting sales of these popular weight-loss medications.
- Dow Job Cuts: Dow announced plans to cut approximately 4,500 jobs under its 'Transform to Outperform' restructuring initiative aimed at enhancing competitiveness and productivity, despite reporting a year-over-year loss in Q4, highlighting the urgency of the restructuring.
- Market Reaction Outlook: The Fed's decision to pause rate cuts may affect market sentiment, and investors should monitor the implications of Trump's nomination and Dow's restructuring plan on the industry in the long term.
Continue Reading